PRTK Paratek Pharmaceuticals Inc.

3.1
+0.01  (+0%)
Previous Close 3.1
Open 3.1
Price To Book -2.54
Market Cap 103,359,072
Shares 33,287,946
Volume 29,433
Short Ratio
Av. Daily Volume 634,853
Stock charts supplied by TradingView

NewsSee all news

  1. Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    BOSTON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

  2. Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019

    -- Third Quarter 2019 NUZYRA® (omadacycline) Net Sales increased 82% versus the Prior Quarter to $3.1 Million -- -- Oral-only CABP Pharmacokinetics Study Initiated-- BOSTON, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Paratek

  3. Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

  4. Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections

    BOSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced

  5. Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    BOSTON, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved November 23, 2011.
Intermezzo
Insomnia
Phase 3 data released July 17, 2017 - all endpoints met.
Omadacycline - oral
Acute bacterial skin and skin structure infections (ABSSSI)
FDA Approval announced October 2, 2018.
Omadacycline
Acute bacterial skin and skin structure infections (ABSSSI)
FDA Approval announced October 2, 2018.
Omadacycline
Community-acquired bacterial pneumonia (CABP)
FDA Approval announced October 2, 2018.
Sarecycline
Severe acne vulgaris
Phase 2 data released October 31, 2019. Comparable levels of clinical success but microbiological responses were generally lower than comparators.
Omadacycline
Urinary tract infections
Phase 2 data released October 31, 2019. Comparable levels of clinical success but microbiological responses were generally lower than comparators.
Omadacycline
Complicated urinary tract infections (cUTI) / acute pyelonephritis

Latest News

  1. Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    BOSTON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

  2. Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019

    -- Third Quarter 2019 NUZYRA® (omadacycline) Net Sales increased 82% versus the Prior Quarter to $3.1 Million -- -- Oral-only CABP Pharmacokinetics Study Initiated-- BOSTON, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Paratek

  3. Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

  4. Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections

    BOSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced

  5. Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    BOSTON, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

  6. Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

    WASHINGTON, Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven

  7. Paratek Mourns Passing of Co-founder Dr. Stuart Levy

    BOSTON, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) mourns the loss of Stuart Levy, M.D., who passed way last week. Dr. Levy co-founded the company more than two decades ago along

  8. Paratek Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    BOSTON, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

  9. Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

  10. Paratek Pharmaceuticals to Present at Robert W. Baird's 2019 Global Healthcare Conference

    BOSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today